Lilly direct-selling Zepbound at $499/mo — compare with 11 other programs

What happens when you stop taking Wegovy?

Reviewed by the glpzoom Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of June 2026; updated when guidance or availability changes.
Wegovy is approved for chronic weight management — meaning it's intended as long-term therapy, not a short course. In the STEP-4 extension trial, patients who stopped Wegovy after a year of treatment regained approximately 67% of their lost weight within a year off the drug, even with continued lifestyle support. The mechanism (appetite suppression) reverses when the drug clears, so hunger and food noise typically return within weeks. Some patients work with clinicians on dose-tapering strategies or maintenance protocols, but there is no proven approach that prevents weight regain after full discontinuation.

Where to start

Licensed US telehealth services that handle this. We may earn a commission when you sign up. See disclosure.

  • Ro logo

    Ro

    from $145/mo
    • Best for insured patients
    • Best for clinical oversight

    Ro Body — branded GLP-1 weight care program

  • Hims logo

    Hims

    from $199/mo
    • Best for cash-pay
    • Best for speed

    Hims Weight Loss — compounded GLP-1 from $199/mo

  • Noom Med logo

    Noom Med

    from $179/mo
    • Best for coaching
    • Best for maintenance

    Noom Med — GLP-1 + behavioral psychology coaching

Drugs referenced

Related questions

  • How much weight can you lose on Wegovy?

    In the STEP-1 trial, adults on Wegovy 2.4mg weekly plus lifestyle changes lost approximately 15% of body weight on average over 68 weeks, vs ~2.4% in the placebo group. About one-third of patients lost ≥20%. Real-world outcomes are typically somewhat lower than trial results because adherence, dose escalation pace, and lifestyle support vary. Most patients s

We may earn a commission when you click links to partners. Affiliate disclosure.